Literature DB >> 21540189

Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the cell surface occurs via a trans-Golgi-proteasome pathway.

Shi-Bin Cheng1, Jeffrey A Quinn, Carl T Graeber, Edward J Filardo.   

Abstract

GPER is a G(s)-coupled seven-transmembrane receptor that has been linked to specific estrogen binding and signaling activities that are manifested by plasma membrane-associated enzymes. However, in many cell types, GPER is predominately localized to the endoplasmic reticulum (ER), and only minor amounts of receptor are detectable at the cell surface, an observation that has caused controversy regarding its role as a plasma membrane estrogen receptor. Here, we show that GPER constitutively buds intracellularly into EEA-1+ endosomes from clathrin-coated pits. Nonvisual arrestins-2/-3 do not co-localize with GPER, and expression of arrestin-2 dominant-negative mutants lacking clathrin- or β-adaptin interaction sites fails to block GPER internalization suggesting that arrestins are not involved in GPER endocytosis. Like β1AR, which recycles to the plasma membrane, GPER co-traffics with transferrin+, Rab11+ recycling endosomes. However, endocytosed GPER does not recycle to the cell surface, but instead returns to the trans-Golgi network (TGN) and does not re-enter the ER. GPER is ubiquitinated at the cell surface, exhibits a short half-life (t½;) <1 h), and is protected from degradation by the proteasome inhibitor, MG132. Disruption of the TGN by brefeldin A induces the accumulation of endocytosed GPER in Rab11+ perinuclear endosomes and prevents GPER degradation. Our results provide an explanation as to why GPER is not readily detected on the cell surface in some cell types and further suggest that TGN serves as the checkpoint for degradation of endocytosed GPER.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21540189      PMCID: PMC3121390          DOI: 10.1074/jbc.M111.224071

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  61 in total

1.  The ubiquitin-specific protease Usp4 regulates the cell surface level of the A2A receptor.

Authors:  Tetyana Milojevic; Veronika Reiterer; Eduard Stefan; Vladimir M Korkhov; Mario M Dorostkar; Eszter Ducza; Egon Ogris; Stefan Boehm; Michael Freissmuth; Christian Nanoff
Journal:  Mol Pharmacol       Date:  2005-12-09       Impact factor: 4.436

2.  Constitutive endocytosis of the metabotropic glutamate receptor mGluR7 is clathrin-independent.

Authors:  Gabriela Lavezzari; Katherine W Roche
Journal:  Neuropharmacology       Date:  2006-08-07       Impact factor: 5.250

3.  Activated somatostatin type 2 receptors traffic in vivo in central neurons from dendrites to the trans Golgi before recycling.

Authors:  Zsolt Csaba; Benjamin Lelouvier; Cécile Viollet; Vincent El Ghouzzi; Kiyoko Toyama; Catherine Videau; Véronique Bernard; Pascal Dournaud
Journal:  Traffic       Date:  2007-05-22       Impact factor: 6.215

4.  Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane.

Authors:  E Filardo; J Quinn; Y Pang; C Graeber; S Shaw; J Dong; P Thomas
Journal:  Endocrinology       Date:  2007-03-22       Impact factor: 4.736

5.  An essential role for constitutive endocytosis, but not activity, in the axonal targeting of the CB1 cannabinoid receptor.

Authors:  Neil A McDonald; Christopher M Henstridge; Christopher N Connolly; Andrew J Irving
Journal:  Mol Pharmacol       Date:  2006-12-20       Impact factor: 4.436

6.  GPR30: a novel indicator of poor survival for endometrial carcinoma.

Authors:  Harriet O Smith; Kimberly K Leslie; Meenakshi Singh; Clifford R Qualls; Chetana M Revankar; Nancy E Joste; Eric R Prossnitz
Journal:  Am J Obstet Gynecol       Date:  2007-04       Impact factor: 8.661

7.  G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.

Authors:  Lidia Albanito; Antonio Madeo; Rosamaria Lappano; Adele Vivacqua; Vittoria Rago; Amalia Carpino; Tudor I Oprea; Eric R Prossnitz; Anna Maria Musti; Sebastiano Andò; Marcello Maggiolini
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

8.  Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.

Authors:  Edward J Filardo; Carl T Graeber; Jeffrey A Quinn; Murray B Resnick; Dilip Giri; Ronald A DeLellis; Margaret M Steinhoff; Edmond Sabo
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

9.  Constitutive traffic of melanocortin-4 receptor in Neuro2A cells and immortalized hypothalamic neurons.

Authors:  Sameer Mohammad; Giovanna Baldini; Susana Granell; Paola Narducci; Alberto M Martelli; Giulia Baldini
Journal:  J Biol Chem       Date:  2006-12-12       Impact factor: 5.157

10.  Clathrin adaptor AP2 regulates thrombin receptor constitutive internalization and endothelial cell resensitization.

Authors:  May M Paing; Christopher A Johnston; David P Siderovski; Joann Trejo
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

View more
  55 in total

1.  Constitutive internalization of the leucine-rich G protein-coupled receptor-5 (LGR5) to the trans-Golgi network.

Authors:  Joshua C Snyder; Lauren K Rochelle; H Kim Lyerly; Marc G Caron; Lawrence S Barak
Journal:  J Biol Chem       Date:  2013-02-25       Impact factor: 5.157

2.  Trans-Golgi Network (TGN) as a regulatory node for β1-adrenergic receptor (β1AR) down-modulation and recycling.

Authors:  Shi-Bin Cheng; Edward J Filardo
Journal:  J Biol Chem       Date:  2012-02-29       Impact factor: 5.157

Review 3.  Twenty years of the G protein-coupled estrogen receptor GPER: Historical and personal perspectives.

Authors:  Matthias Barton; Edward J Filardo; Stephen J Lolait; Peter Thomas; Marcello Maggiolini; Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-25       Impact factor: 4.292

Review 4.  GPER modulators: Opportunity Nox on the heels of a class Akt.

Authors:  Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-08       Impact factor: 4.292

Review 5.  Rapid steroid hormone actions initiated at the cell surface and the receptors that mediate them with an emphasis on recent progress in fish models.

Authors:  Peter Thomas
Journal:  Gen Comp Endocrinol       Date:  2011-11-29       Impact factor: 2.822

Review 6.  Extranuclear signaling by ovarian steroids in the regulation of sexual receptivity.

Authors:  Paul E Micevych; Kevin Sinchak
Journal:  Horm Behav       Date:  2018-05-18       Impact factor: 3.587

7.  G protein-coupled receptor 30 (GPR30) forms a plasma membrane complex with membrane-associated guanylate kinases (MAGUKs) and protein kinase A-anchoring protein 5 (AKAP5) that constitutively inhibits cAMP production.

Authors:  Stefan Broselid; Kelly A Berg; Teresa A Chavera; Robin Kahn; William P Clarke; Björn Olde; L M Fredrik Leeb-Lundberg
Journal:  J Biol Chem       Date:  2014-06-24       Impact factor: 5.157

8.  Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells.

Authors:  George Notas; Marilena Kampa; Vassiliki Pelekanou; Maria Troullinaki; Yves Jacquot; Guy Leclercq; Elias Castanas
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

9.  Estradiol accelerates the effects of fluoxetine on serotonin 1A receptor signaling.

Authors:  Qian Li; Nicole R Sullivan; Carrie E McAllister; Louis D Van de Kar; Nancy A Muma
Journal:  Psychoneuroendocrinology       Date:  2012-12-05       Impact factor: 4.905

10.  The effects of (-)-epicatechin on endothelial cells involve the G protein-coupled estrogen receptor (GPER).

Authors:  Aldo Moreno-Ulloa; David Mendez-Luna; Ernesto Beltran-Partida; Carmen Castillo; Gustavo Guevara; Israel Ramirez-Sanchez; José Correa-Basurto; Guillermo Ceballos; Francisco Villarreal
Journal:  Pharmacol Res       Date:  2015-08-21       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.